SI2297115T1 - Dialkoksikinazolinski derivati kot inhibitorji kdr - Google Patents

Dialkoksikinazolinski derivati kot inhibitorji kdr

Info

Publication number
SI2297115T1
SI2297115T1 SI200931257T SI200931257T SI2297115T1 SI 2297115 T1 SI2297115 T1 SI 2297115T1 SI 200931257 T SI200931257 T SI 200931257T SI 200931257 T SI200931257 T SI 200931257T SI 2297115 T1 SI2297115 T1 SI 2297115T1
Authority
SI
Slovenia
Prior art keywords
dialkoxyquinazoline
derivatives
kdr inhibitors
kdr
inhibitors
Prior art date
Application number
SI200931257T
Other languages
English (en)
Inventor
Wei-Guo Su
Weihan Zhang
Xiaoqiang Yan
Yumin Cui
Yongxin Ren
Jifeng Duan
Original Assignee
Hutchison Medipharma Enterprises Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Enterprises Limited filed Critical Hutchison Medipharma Enterprises Limited
Publication of SI2297115T1 publication Critical patent/SI2297115T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200931257T 2008-05-09 2009-05-08 Dialkoksikinazolinski derivati kot inhibitorji kdr SI2297115T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/118,019 US7829574B2 (en) 2008-05-09 2008-05-09 Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
EP09743783.4A EP2297115B1 (en) 2008-05-09 2009-05-08 Dialkoxyquinazoline derivatives as kdr inhibitors
PCT/US2009/043347 WO2009137797A2 (en) 2008-05-09 2009-05-08 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
SI2297115T1 true SI2297115T1 (sl) 2015-10-30

Family

ID=41265455

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931257T SI2297115T1 (sl) 2008-05-09 2009-05-08 Dialkoksikinazolinski derivati kot inhibitorji kdr

Country Status (21)

Country Link
US (3) US7829574B2 (sl)
EP (1) EP2297115B1 (sl)
JP (2) JP5856842B2 (sl)
KR (2) KR101686679B1 (sl)
AU (1) AU2009244130B2 (sl)
BR (1) BRPI0908675B1 (sl)
CA (1) CA2723148C (sl)
CY (1) CY1117222T1 (sl)
DK (1) DK2297115T3 (sl)
ES (1) ES2550245T3 (sl)
HR (1) HRP20150954T1 (sl)
HU (1) HUE025723T2 (sl)
MX (2) MX2010012168A (sl)
MY (1) MY155566A (sl)
NZ (1) NZ588900A (sl)
PL (1) PL2297115T3 (sl)
PT (1) PT2297115E (sl)
RU (1) RU2506261C2 (sl)
SI (1) SI2297115T1 (sl)
TW (1) TWI458724B (sl)
WO (1) WO2009137797A2 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
ES2527940T3 (es) * 2009-02-11 2015-02-02 Merck Patent Gmbh Nuevas carboxamidas amino-azaheterocíclicas
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
CN105461702A (zh) 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CA3000988A1 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2017189483A1 (en) * 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
WO2019014044A1 (en) 2017-07-12 2019-01-17 The Johns Hopkins University ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
CN116987070A (zh) * 2018-03-30 2023-11-03 杭州领业医药科技有限公司 呋喹替尼的共晶、其制备方法、组合物和用途
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN110898065A (zh) * 2019-11-25 2020-03-24 南通大学 呋喹替尼或其盐在制备治疗脉络膜新生血管药物中的用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
ATE482946T1 (de) * 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1326860A1 (en) * 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives
WO2002030924A1 (en) * 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002070477A1 (fr) 2001-03-01 2002-09-12 Ono Pharmaceutical Co., Ltd. Acide 2-methylindole-4-acetique, son procede de production et procede pour produire un produit intermediaire de celui-ci
WO2003048159A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
WO2005005395A2 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2551508C (en) * 2003-12-23 2011-08-09 Pfizer Inc. Novel quinoline derivatives
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
US20080268460A1 (en) * 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
US20070299092A1 (en) 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
WO2007066181A2 (en) 2005-12-05 2007-06-14 Pfizer Products Inc. Methods of preparing a vegf-r inhibitor
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2007133773A2 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of cdki pathway inhibitors
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

Also Published As

Publication number Publication date
BRPI0908675B1 (pt) 2022-01-25
TWI458724B (zh) 2014-11-01
WO2009137797A3 (en) 2010-02-25
US7829574B2 (en) 2010-11-09
CA2723148C (en) 2015-01-20
BRPI0908675A2 (pt) 2015-08-04
MX2014001023A (es) 2014-05-22
KR20110013381A (ko) 2011-02-09
US8497372B2 (en) 2013-07-30
US8212033B2 (en) 2012-07-03
RU2010150345A (ru) 2012-06-20
EP2297115A2 (en) 2011-03-23
PL2297115T3 (pl) 2015-12-31
ES2550245T3 (es) 2015-11-05
HRP20150954T1 (hr) 2015-10-09
US20110015213A1 (en) 2011-01-20
PT2297115E (pt) 2015-10-26
EP2297115A4 (en) 2012-03-14
RU2506261C2 (ru) 2014-02-10
EP2297115B1 (en) 2015-07-22
KR101686679B1 (ko) 2016-12-14
MY155566A (en) 2015-10-30
JP2014177499A (ja) 2014-09-25
HUE025723T2 (en) 2016-04-28
TW201002694A (en) 2010-01-16
JP5856842B2 (ja) 2016-02-10
CY1117222T1 (el) 2017-04-05
JP2011519956A (ja) 2011-07-14
WO2009137797A2 (en) 2009-11-12
US20090281130A1 (en) 2009-11-12
US20120238572A1 (en) 2012-09-20
MX340021B (es) 2016-06-22
KR20160045925A (ko) 2016-04-27
DK2297115T3 (en) 2015-08-10
NZ588900A (en) 2012-12-21
MX2010012168A (es) 2011-02-18
CA2723148A1 (en) 2009-11-12
AU2009244130A1 (en) 2009-11-12
AU2009244130B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
HK1256310A1 (zh) N-磺酰基吡咯衍生物
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
EP2376494A4 (en) DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
PT2308877E (pt) Derivados de imidazopiridin-2-ona
SG10201506608RA (en) 3-deazaneplanocin derivatives
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
IL210406A0 (en) Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives
EP2291078A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
SI2297115T1 (sl) Dialkoksikinazolinski derivati kot inhibitorji kdr
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
IL213424A0 (en) Quinazolinamide derivatives
EP2292613A4 (en) DIHYDROINDOLINONDERIVATE
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
GB0821710D0 (en) Derivatives of dihydroindolone
HUP0800376A2 (en) Sulfonyl-quinoline derivatives